Alloksys announces first patients enrolled in the continuation of the APPIRED III clinical trial with RESCAP® in patients undergoing cardiothoracic surgery
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with longer administration of RESCAP® (up to 96 hours), benefits such as accelerated recovery and reduced acute kidney injury (AKI) is expected in all patients with underlying Chronic Kidney Disease (CKD) […]
Alloksys announces the enrollment of the first patients in the APhIRI II study with Alkaline phosphatase treatment of patients undergoing kidney transplantation from a deceased donor
July 1-2024. Alloksys anticipates that a treatment with RESCAP® reduces the immediate complications resulting from the kidney transplantation procedure and improves the long-term graft survival. Introduction An important determinant of graft survival is ischemia reperfusion injury. Ischemia and sequential reperfusion are inherent consequences of any transplantation procedure, in particular when the transplanted kidney is donated […]
